XOMA Royalty’s Post

Despite the high prevalence of female sexual arousal disorder (FSAD), which impacts approximately 20% of women in the U.S, there are no FDA-approved pharmacological treatments for FSAD. Publication of this pivotal manuscript in an important peer-reviewed medical journal further underscores the potential of Sildenafil Cream to address this unmet need and improve outcomes for women with FSAD. It also highlights the importance of these groundbreaking data and their potential to advance the field by providing insights into the patient population and the most meaningful patient-reported outcome measures for assessing improvement. Working closely with the FDA, we continue activities to support progress towards our planned Phase 3 clinical study of Sildenafil Cream, which would be the first ever Phase 3 pivotal study of a therapeutic candidate for the treatment of arousal disorder in women. Read more here: https://bit.ly/3VRh3aA

We are pleased to announce the publication of our Phase 2b study efficacy results of topical Sildenafil Cream 3.6%, which is being developed for the treatment of female sexual arousal disorder (FSAD), in Obstetrics & Gynecology, the official publication of the American College of Obstetricians and Gynecologists (ACOG). The Phase 2b clinical study showed that topical Sildenafil Cream improved outcomes among women with FSAD, most significantly in a subset of women both with and without concomitant decreased desire. In an exploratory post-hoc analysis of this group, topical Sildenafil Cream significantly increased sexual arousal sensation and reduced sexual distress, as well as improved desire and orgasm. Access the full published study manuscript here: https://bit.ly/3VRh3aA

Indocyanine Green for Assessment of Ureteral Vascularity Can Reduce the Rate of Ureteral Complications in Patients Undergoing Extended Hysterectomy Objectives: This study aimed to evaluate the effectiveness of using indocyanine green (ICG) for assessing ureteral vascularity to reduce ureteral complications in patients undergoing extended hysterectomy for deep endometriosis or oncological indications. Methods: A retrospective-prospective cohort study was conducted at the Centre of Gynecology in Opole, Poland, involving 555 patients who underwent hysterectomy from 2020 to 2023. Patients were categorized based on the Querleu-Morrow classification. ICG was used intraoperatively for vascular assessment in patients with deep endometriosis undergoing wide ureter dissection typical of Type C hysterectomy. Results: Ureteral complications occurred in 12 (2.2%) patients, with a significantly lower complication rate in those who underwent ICG testing (1.7%) compared to those who did not (22.7%, p = 0.001). Prophylactic double-J stenting further reduced the risk of complications. Conclusions: The use of ICG for intraoperative assessment of ureteral vascularity significantly reduces the risk of ureteral complications in complex hysterectomies. Further studies are needed to confirm these findings. #ureteralvascularity #intraoperativeassessment #icg #indocyaninegreen #verdye #betterpatientoutcomes #diagnosticgreen https://lnkd.in/eMKJkjbi

I am thrilled to share with you our new paper on prenatal diagnosis and genetic evaluation of fetal BAs, published in the International Journal of Obstetrics and Gynecology. We compared the performance and accuracy of ES and CMA in identifying different types of BAs. We conducted a meta-analysis of 11 studies, involving 779 fetuses, and found that ES, along with imaging methods such as MRI and ultrasonography, has a much higher diagnostic rate (26.53%) for BAs than CMA (3.46%). The risk difference between ES and CMA for complex BAs was 0.36 (95% CI 0.24–0.47), showing its clear advantage. Our results suggest that ES is a valuable tool for genetic testing and prognosis of congenital disorders in fetuses with complex BAs detected by imaging techniques. I am grateful to all the coauthors and researchers who contributed to this study: Behnaz Moradi, M.D, Morteza Sanei Taheri, Mahsa Heidari-Foroozan, Armin Ariaei, Masoumeh Banihashemian, Ali Rashidinejad, Mohammad Ali Kazemi You can access the full paper here: https://lnkd.in/dmEXE7FH #mri #ultrasound #prenatal #exome_sequencing #genetic_screening #brain_anomalies

📢 A New Special Issue led by Dr. Nicolae Gica is now open for submissions! "Case Reports in Obstetrics and Gynecology" https://lnkd.in/gNHziJFp For this Special Issue, we welcome interesting rare case reports/interesting images in the fields of different maternal and fetal pathologies, gynecologic oncology, and new imaging methods in obstetrics and gynecology.

Can’t wait to be guided by experts who have devoted their careers to combating this formidable disease at IMUNON’s first Ovarian Cancer R&D Day. 2 points that are critical to set the stage: 1) The standard of care in Ovarian Cancer has remained largely unchanged for the past 25 years and 2) until very recently no trial in ovarian cancer has demonstrated an overall survival benefit, including the historical trials that set the current first-line treatment standard. Together we’ll will envision a future where we significantly impact the lives of those affected by this aggressive and often fatal condition. #ovariancancer

This week on BackTable OBGYN: Dr. Keith Isaacson , a specialist in Reproductive Endocrinology and Infertility, shares his knowledge about the complexities of diagnosing and treating adenomyosis, emphasizing surgery, medical treatments, and research in the field. Dr. Isaacson describes the pivots in the field’s understanding of adenomyosis and endometriosis, including the impact of these conditions on fertility and potential treatment pathways. Adenomyosis has been redefined in the past five years as a disease that affects women of all reproductive ages and causes dysmenorrhea, heavy menstrual bleeding, and infertility. Because the disease is found in the myometrium of the uterus, it has historically been difficult to diagnose unless through pathology following hysterectomy; however, imaging has since improved and there are now criteria seen on ultrasound that are consistent with adenomyosis. Dr. Isaacson then discusses the differences and misconceptions about adenomyosis compared to endometriosis. Additionally, the episode touches on the evolution of treatment strategies over the years, including medical therapy versus surgery. Furthermore, Dr. Isaacson highlights the crucial role of research in uncovering disease pathophysiology and new therapeutic approaches. Listen at the link below to learn more! https://lnkd.in/dx-k97mB Also listen on: Apple: https://lnkd.in/dH4SKB2y Spotify: https://lnkd.in/dAi9bxU9 #OBGYN #MedEd Amy Park, MD Mindy Christianson Aarathi Cholkeri-Singh, M.D., FACOG Erica M. Angela Chaudhari MD Mallory Stuparich, MD, FACOG Charles E. Miller, MD FACOG Kurian Thott M.D.,FACOG Karla Loken DO OBGYN FACOOG Paula Jaye Doyle, M. D. FPMRS Mackenzie Botz Camille A. Clare MD MPH CPE FACOG (she/her/hers)

Nearly half of the brain MRI scans performed in pediatric endocrinology patients are unnecessary, with repeated imaging often providing no new clinical insights, according to a study that emphasizes the need for clearer guidelines to reduce the overuse of MRIs. View the complete article below ⤵️ #GrowthHormone #GrowthHormoneDeficiency #PediatricEndocrinology #MRI

Why do over one million people trust SiderAL Sucrosomial Iron each day? Because it's supported by over 160 preclinical and clinical studies, showing a 4.5% side effect profile across a variety of specialties (oncology, nephrology, cardiology, gastroenterology, obstetrics & gynecology). Patients looking to avoid the typical pitfalls of iron supplementation have another treatment option before resorting to IV therapy. Check it out here ⬇ https://lnkd.in/e76cJ7fA #anemia #irondeficiency

The Pivotal Role of Cytokines in Bovine Cystic Ovarian Disease: Pathogenesis, Implications, and Therapeutic Potential Link: https://lnkd.in/gxGpfMBq Explore more insights on the Gynecology. Visit our blog for more interesting updates: https://gynecology.blog/ #gynaecology #reproductivehealth #Cytokines